share_log

Citigroup Initiates Coverage On Travere Therapeutics With Neutral Rating, Announces Price Target of $7

Citigroup Initiates Coverage On Travere Therapeutics With Neutral Rating, Announces Price Target of $7

花旗集团以中性评级启动对Travere Therapeutics的报道,宣布目标股价为7美元
Benzinga ·  2023/11/20 05:55

Citigroup analyst Carly Kenselaar initiates coverage on Travere Therapeutics (NASDAQ:TVTX) with a Neutral rating and announces Price Target of $7.

花旗集团分析师卡莉·肯塞拉尔以中性评级开始对Travere Therapeutics(纳斯达克股票代码:TVTX)进行报道,并宣布目标股价为7美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发